TP53 and neoplasm: Studies using a similar model that allows both inducible and reversible expression of oncogenic KRASG12D have revealed that this oncogene is required not only for tumor initiation, but also for tumor maintenance, independently of the presence of additional mutations (such as inactivation of Trp53 or other tumor suppressor genes) (8).